Genset SA

MELBOURNE - Pharmaxis Ltd. chief executive Gary Phillips told PharmAsia News that the bioventure has “a long runway ahead of it thanks to the Boehringer cash” and its extensive portfolio of amin

High-value, early-stage dealmaking is something of an oxymoron in the biopharmaceutical world; very few research collaborations or even preclinical licensing deals sport large up-front payments. The h

Research directors mulling mounting expenses and lagging productivity are revisiting the notion of consortia—considering whether and how Big Pharma companies and possibly some of the larger biotech fi

A $100 million start-up is betting that its technology for measuring millions of SNPs will create the predictive patterns that pharmacogenomics has as yet failed to deliver. t's the rare start-up that